pharma · Type 1 Diabetes Mellitus · Prophylaxis of Renal Allograft Rejection · ELDN
Eledon Pharmaceuticals
Eledon Pharmaceuticals is a pharma organization headquartered in Irvine, USA. It trades on NYSE under ticker ELDN. Primary therapeutic focus areas include Type 1 Diabetes Mellitus, Prophylaxis of Renal Allograft Rejectio
Irvine, USA HQ
2020 Founded
42 Employees
Public company Type
ELDN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Irvine, USA
- Founded
- 2020
- Employees
- 42
- Programs
- 9
- Drugs
- 11
- Patents
- 0
AT-1501
Phase 2 · small molecule · Prevention of Rejection in Kidney Transplant
AT-1501 for Prevention of Rejection in Kidney Transplant is a Phase 2 program (small_molecule) at Eledon Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code AT-1501-K102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Eledon Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Prevention of Rejection in Kidney Transplant
- Status
- active
- Trials
- 1